Frequency Therapeutics Corporate Overview - September 2020
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Frequency Therapeutics
Corporate Overview
September 2020
Copyright Frequency Therapeutics, Inc. 1
FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the treatment potential of FX-322, the design and enrollment of the Phase 2a clinical trial of FX-322, the timing of top-line data from the Phase 2a clinical trial and timing of presentation of results of the exploratory study in Germany, the novelty of the exploratory study in Germany, the implications of the results of the exploratory Germany study in combination with our other trials, the therapeutic levels of FX-322 predicted in the exploratory Germany study, the results and implications of the Phase 1/2 durability of response data, the timing of the FX-322 clinical study in patients with age related hearing loss, the ability of our technology platform to provide patient benefit, the impact of COVID-19 on the Company’s on-going and planned clinical trials and business, future milestone and royalty payments under the license and collaboration agreement with Astellas Pharma Inc. (“Astellas”), the sufficiency of the Company’s cash, cash equivalents and short- term investments, estimates of the size of the hearing loss population and population at risk for hearing loss, the timing of the remyelination program, and the potential application of the PCA platform to other diseases. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: Frequency Therapeutics (the “Company”) has incurred and will continue to incur significant losses and is not and may never be profitable; need for additional funding to complete development and commercialization of any product candidate; the Company’s dependence on the development of FX-322; the unproven approach of the PCA platform; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; the impact of the COVID-19 impact; failure to identify additional product candidates; new or changed legislation; failure to maintain Fast Track designation for FX-322 and such designation failing to result in faster development or regulatory review or approval; costly and damaging litigation, including related to product liability, intellectual property or brought by stockholders; dependence on Astellas for the development and commercialization of FX-322 outside of the United States; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with laws and regulations, including healthcare and environmental, health, and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property; security breaches or failure to protect private personal information; attracting and retaining key personnel; and ability to manage growth. These and other important factors discussed under the caption “Risk factors” in the Company’s Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 12, 2020 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management’s estimates as of the date of this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this presentation. Copyright Frequency Therapeutics, Inc. 2
Frequency Today
FX-322 program for sensorineural hearing loss in Phase 2a clinical development
• Phase 2a study ongoing, fully enrolled; read out in Q2 2021
• Phase 1/2 results provided evidence of hearing restoration; favorable safety profile
• Planning for near-term FX-322 studies in additional patient populations
• FDA Fast Track designation
Additional opportunities across multiple degenerative diseases
• Multiple sclerosis program advancing toward IND; target submission H2 2021
• Broad IP portfolio in hearing and additional applications
Operating runway into 2023
• $195.4 million in cash, cash equivalents and short-term investments (as of June 30, 2020)
• $40.1 million in net proceeds raised in private placement in July 2020
• Potential development milestones related to Astellas ex-US FX-322 collaboration including $90M
at first Phase 2b dosing in Europe & Asia and $140M for the first Phase 3 dosing in Europe & Asia
Copyright Frequency Therapeutics, Inc. 3
Key Recent Advances in FX-322 Clinical Development
Data presented
Sept. 13, 2020
Demonstration of
effective delivery to the Preliminary evidence of
target tissue longer-term durability
• Exploratory study of patients undergoing cochlear • Post P1/2 study word recognition (WR) data
impact surgery to determine if cochlear drug obtained in five patients 13- 21 months following
levels can be directly measured administration
• 4/5 subjects maintained improvements in WR
Key findings: scores
• Measurement of cochlear fluid confirmed • Three of four patients who responded to FX-
successful drug delivery to cochlea in all samples 322 maintained stat sig benefit
analyzed
• 87% average increase from original baseline
• Drug levels predicted to result in • Same three subjects showed 10-15 dB
therapeutic activity improvements at 8kHz
Copyright Frequency Therapeutics, Inc. 4
Origins of Frequency Therapeutics
Tissue-Specific, Pre-programmed Stem Cells
Decoding Intestinal Enabling Cochlear Frequency
Regeneration Regeneration Therapeutics
Langer and Karp publish Same cues reactivate Small molecule
small molecules activate normally inactive therapeutics show clinical
intestinal progenitors progenitors in the cochlea proof of concept
Niche-independent high- Clonal Expansion of Lgr5-Positive
purity cultures of Lgr5+ Cells from Mammalian Cochlea and
intestinal stem cells and High-Purity Generation of Sensory
their progeny Hair Cells
Copyright Frequency Therapeutics, Inc. 5
Regenerative Approach with Broad Potential
Brain
Ear Eye
Lung Skin Progenitor cells are stem cells
that are pre-programmed to
Intestine Bone perform a specific activity
Muscle Cartilage
Potential to address a range
of degenerative diseases
Copyright Frequency Therapeutics, Inc. 6
Frequency Progenitor Cell Activation (PCA) Approach
Inactive Progenitor Cell
Inactive ACTIVATED
Progenitor Progenitor
Asymmetric
division using
native programs
Functional Target Cell
Combinations of small molecules
designed to activate progenitor cells
Copyright Frequency Therapeutics, Inc. 7
Reducing the Complexity of Regenerative Medicine
Harnessing No Change Ease of
Innate Biology To Genome Manufacturing
Progenitors already Activating native programs, Use of small
located within target reducing safety concerns molecules: no need to
tissue remove or grow cells
ex vivo
Copyright Frequency Therapeutics, Inc. 8
Our Pipeline
DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3
Sensorineural hearing
loss (FX-322)
DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3
Multiple Sclerosis
Copyright Frequency Therapeutics, Inc. 9
Hearing Restoration Program: Preclinical Validation Copyright Frequency Therapeutics, Inc. 10
Cochlear Function: Hearing Different Frequencies
Healthy Cochlea »
Oval window base
Schematic of
expanded cochlea
Apex
Round window
20,000 Hz 1,500 Hz 20 Hz
(high frequency) (medium frequency) (low frequency)
Copyright Frequency Therapeutics, Inc. 11Impact of Damage to Cochlear Hair Cells
Healthy Cochlea Damaged Cochlea
Inner Hair Cells (IHCs)
Outer Hair Cells (OHCs)
“Analysis of hair cells, auditory nerve fibers and strial tissues … shows that the degree of hearing loss is
well predicted from the amount of hair cell loss.” Journal of Neuroscience, July 2020
Copyright Frequency Therapeutics, Inc. DOI: https://doi.org/10.1523/JNEUROSCI.0937-20.2020 12Profound, Unexpected Synergy
Cochlear Progenitor Proliferation (Lgr5-GFP)
Culture Media
Strong synergy
seen between Wnt Activation
(glycogen synthase kinase-3
pathways activated (GSK3) Inhibitor; NCE)
by small molecules
HDAC Inhibition
(sodium valproate)
Wnt Activation and
HDAC inhibition
HDAC = Histone deacetylase HIGH SYNERGY
In vitro mouse model testing
NCE = new chemical entity
Copyright Frequency Therapeutics, Inc. Cell Rep. 2017 Feb 21;18(8):1917-1929. doi: 10.1016/j.celrep.2017.01.066 13FX-322 Program: Aiming to Repair Underlying Pathology • Progenitors in place despite loss of hair cells • FX-322 molecules aim to activate genetic pathways to regenerate missing hair cells Copyright Frequency Therapeutics, Inc. 14
Strong Pre-Clinical Validation
Test Outcome
In vitro
Adult human inner ear tissue Created new hair cells
In vivo
Restored hair cells and hearing across all
Adult deafened mice
frequencies
Achieved active levels in the cochlea
Therapeutic drug levels
in multiple species
Copyright Frequency Therapeutics, Inc. 15Clinical Program Copyright Frequency Therapeutics, Inc. 16
FX-322 Administration and Concentration
Quick intratympanic injection into the middle ear FX-322 concentrates in the highest
frequency region, critical for sound clarity
1,000 Hz 2,000 Hz
Inner ear 500 Hz
3,000 Hz
Cochlea 250 Hz
Middle ear
20,000 Hz
Needle 4,000 Hz
Outer ear 16,000 Hz
Ear drum
Round window 14,000 Hz
12,000 Hz
Eustachian tube
10,000 Hz
8,000 Hz 6,000 Hz
US Phase 1/2 Study FX-322-201
Copyright Frequency Therapeutics, Inc. Analysis in partnership with Mass Eye and Ear Institute Temporal Bone Bank 17Hearing is Measured Using Validated Tests
Audibility (Loudness) Intelligibility (Clarity)
measured with pure tones measured with word recognition and words-in-noise tests
Word Recognition Test:
• List of 50 monosyllabic words
• Single words played in quiet
Words-in-Noise Test:
• Standard, clinically accepted
measure
• Background noise from
multiple voices
• Played at different signal-to-
noise ratios
Copyright Frequency Therapeutics, Inc. 18Critical Information Lost at High Frequencies
“Oh say can you see … by the dawn’s early light”
20
16
Spectrogram
Frequency (kHz)
12
of Sound
8
4
0.5 1 1.5 2 2.5 3
Time (Secs)
Copyright Frequency Therapeutics, Inc. Source: Monson et al (2014) The perceptual significance of high-frequency energy in the human voice. Frontiers in Psychology, 5, 587 19Successful Phase 1/2 Study Completed
Screening NIHL/SSNHL
Mild to Moderately Severe
Study Overview
• Safety in patients with
Single No
sensorineural hearing loss Injection Injection
FX-322 Placebo
• Stable patients N = 15 N=8 15 drug, All 23
8 placebo patients
• Assessed hearing by word
Day 1 | Dose
testing and pure tones
Follow-up Visits
Days 15, 30, 60, 90
Copyright Frequency Therapeutics, Inc. 20Clinically Meaningful Improvement in Word Recognition
Mild Hearing Loss Moderate to Moderately Severe
Hearing Loss
• 14 patients (5 placebo)
• 9 patients (3 placebo)
• Typically very high word
recognition scores (45+ words) • All treated subjects showed increases
in word recognition
• Ceiling effect: Limited room for
improvement • 4 of 6 showed statistically significant
and clinically meaningful improvement
• No change in placebo
• No change in untreated ear
Copyright Frequency Therapeutics, Inc. 21Clinically Meaningful Improvements in Word Recognition
Absolute Word Recognition Scores
50
47 *
40 Clarity of Sound
39 * 38 Used word tests
30
34 * in a quiet background
29
26
20 Baseline – Correct
20 words out of 50
16 *
14
10 12 Day 90 – Correct
words out of 50
7 8
0 Test/retest variability is one
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 standard deviation, which for a 50-
word list is ~ 3 words
*Statistically significant and clinically meaningful improvements in word recognition
Copyright Frequency Therapeutics, Inc. 22Statistically Significant Improvement in Sound Clarity
Word Recognition
50
40
Clarity of Sound
Improvement
30 Used word tests
% Change from Baseline
in a quiet background
20 [all patients]
10
Placebo
0 FX-322
-10 p=0.010
-20
0 Day
15 15 Day
3030 45 Day
6060 75 Day9090
Copyright Frequency Therapeutics, Inc. US Phase 1/2 Study FX-322-201 23Clear Improvement Trend in Words-in-Noise
Words-in-Noise
40
Clarity of Sound
Improvement
30
Used word tests
% Change from Baseline
20 in a noisy background
[all patients]
10
Placebo
0
FX-322
-10
p=0.211
-20
0 10 Day 15 20 30
Day 30 40 50 Day 6060 70 80 Day 90 90
Copyright Frequency Therapeutics, Inc. US Phase 1/2 Study FX-322-201 24Pure Tone Improvements at Highest Tested Frequency
Percent of Patients with 10dB
Improvement at 8000 Hz
4 / 13
35% subjects
30%
Loudness of Sound
measured pure tones
25%
20%
• Standard frequency range was
15% measured (500 – 8000 Hz)
10% • Consistent pure tone
0/7 improvements observed at
5%
subjects 8000 Hz in only FX-322 subjects
0%
Placebo FX-322
Analysis includeds subjects with a measurable baseline hearing deficit at 8000 Hz
Copyright Frequency Therapeutics, Inc. US Phase 1/2 Study FX-322-201 25New Data Show Sustained, Clinically Meaningful
Improvements in Word Recognition
Absolute Word Recognition Scores
50
50W Clarity of Sound
47
50W
Used word tests
40 25W*
39
50W
in a quiet background
50W 50W 38 38
34 25W*
35
30 50W
Baseline – Correct
30 50W 29 50W words out of 50
26
50W Day 90 – Correct
20 22 words out of 50
50W 20
50W
16 50W 1-2 years – Correct
14 words out of 50
10 12
50W
Month 7 Month Month Month Month Test/retest variability is one
16** 21** 19** 13** 21** standard deviation, which for a 50-
0
word list is ~ 3 words
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5
*25W = 25 Word test performed outside an official study site at 13-18 months after dosing; results scaled to 50 words
50W = 50 Word test performed under a formal protocol at original study site at 18-21 months after dosing
**Since FX-322 dosing
Copyright Frequency Therapeutics, Inc. 26New Data Show Sustained, Clinically Meaningful
Improvements in Word Recognition
• Follow-up study data presented at Sept. 2020 American
Academy of Otolaryngology (AAO) Annual Meeting
• Hearing signal observed in subjects from previous Phase
1/2 study appears to be maintained
• 4/5 subjects maintained improvements in WR scores
• 3/4 subjects showed Thornton-Raffin improvements and had
an 87% average increase from original baseline
• These same 3 subjects showed 10-15 dB improvements
at 8kHz
Copyright Frequency Therapeutics, Inc. 27Clinical Data Confirms FX-322 Delivery to Cochlea
• Exploratory study in Germany to see if cochlear
drug levels can be directly measured
• Patients undergoing cochlear implant
surgery receive standard FX-322 injection
• Cochlear fluid (perilymph) obtained
Key findings:
• Measurement of cochlear fluid confirmed
successful drug delivery to cochlea in all
samples analyzed
• Drug levels predicted to result in
therapeutic activity
Taken together with Phase 1/2 study, we believe this is the first known evidence of a
pharmacokinetic / pharmacodynamic effect of a potential hearing restoration therapeutic
Copyright Frequency Therapeutics, Inc. 28Key Elements in FX-322 Development:
Leadership in Hearing Drug Development
Effective Favorable Clinically meaningful Preliminary evidence
delivery to the safety profile improvements in of longer-term
target tissue hearing function durability
Copyright Frequency Therapeutics, Inc. 29Phase 2a Study – Objectives
Further establish Evaluate Clarify endpoints and
hearing signal repeat dosing patient population
Copyright Frequency Therapeutics, Inc. 30FX-322 Study - Phase 2a Design
Screening NIHL/SSNHL
Mild to Moderately Severe • Double-blind, placebo-controlled,
multi-center, adults ages 18-65
• All subjects have meaningful
Randomize 1:1:1:1
word recognition deficits
• Efficacy and exploratory endpoints
• Word recognition
FX-322 FX-322 FX-322 Placebo
• Words-in-noise
1X 2X 4X 4X
N = 24 N = 24 N = 24 N = 24 • Pure tone audiometry (0.25-16kHz)
• Tinnitus questionnaire
• QoL questionnaires
Follow-up Visits
Days 15, 30, 60, 90, 120, 150, 180, 210
Copyright Frequency Therapeutics, Inc. 31Hearing Loss Overview Copyright Frequency Therapeutics, Inc. 32
Improvement in Hearing Clarity is the Major Unmet
Need Among Hearing Loss Patients
“I can hear you…
I just can’t understand you.”
Copyright Frequency Therapeutics, Inc. 33Opportunity to Treat Substantial Patient Population (US)
2018 Hearing Loss Prevalence – US Adults
• ~40m SNHL patients – expected 30
26
to grow by 20% by 2030 = not treated
= treated with hearing aids
• Opportunity to treat patients
Patients (millions)
20
both with and without hearing 15
aids
10
• Significant opportunity to
expand treatment rate among
mild patients 0
Mild Moderate / Severe
• No restorative therapies exist to Hearing Loss Hearing Loss
treat underlying cause of SNHL
Notes: Prevalence based on self-reported hearing loss; sensorineural accounts for >90% of hearing loss
Source: National Health Interview Survey (sample size of 35,000 households); Census Bureau; NIH; NCBI
Copyright Frequency Therapeutics, Inc. 34Commercial Overview
Introduction of an injectable therapeutic for hearing loss will require ear, nose and throat (ENT) doctors for prescription
and administration, while continuing to drive diagnosis and monitoring through audiologists
CURRENT STATE FUTURE STATE
• FX-322 aims to improve hearing for
• Hearing aids are the primary treatment
those with acquired SNHL including
for hearing loss; limited in reaching
overall sound clarity, a major unmet
frequencies that impact sound clarity
need for hearing loss patients
• ENTs have no approved treatment
interventions to offer mild, moderate, or • Procedure would be integrated into
moderately severe hearing loss patients existing ENT office practices for patients
with or without hearing aids
• Audiologists are the primary source of
• Audiologists role in diagnosing hearing
diagnosis, treatment and monitoring
loss and patient engagement likely to
Only half of hearing loss pts have grow with increased treatment options
been formally diagnosed/treated in
part due to a lack of available
treatment options*
Frequency’s focus includes market insight generation, planning & development, and stakeholder engagement
Confidential
Copyright | Frequency Therapeutics, Inc. 35 *CDC/NCHS 35Hearing Health Impacts Brain Health
July, 2020
Risks Associated with
Hearing loss is the largest potentially modifiable risk
factor for developing dementia Untreated Hearing Loss
50% 41%
DEMENTIA DEPRESSION
JAMA Nov 8, 2018
Deal J, et al. Incident Hearing Loss and Comorbidity. A Longitudinal Administrative Claims Study.
Copyright Frequency Therapeutics, Inc. 36Broad Potential of Progenitor Cell Activation Approach Copyright Frequency Therapeutics, Inc. 37
Remyelination Program for Multiple Sclerosis
Building on strong progenitor Target IND submission
biology foundation in 2H21
• Scripps Institute applied PCA • Building on expertise in discovering
approach to brain progenitors and developing synergistic
combinations of small molecules
• Validated in multiple animal models
• Worldwide license and ongoing
• Clinically validated using a single
research partnership with Scripps
agent (Lancet Dec ’17)
Copyright Frequency Therapeutics, Inc. 38Moving Forward Copyright Frequency Therapeutics, Inc. 39
Summary
+ +
Hearing Signal Established Large Market
Potential first-in-class regenerative Addressable market
treatment to restore hearing of >30 million people in the U.S.
+ +
Ex-US Partnership Platform Potential
Global development and PCA platform with potential
commercial partner; substantial to treat patients with numerous
royalties and milestones, degenerative diseases
U.S. rights retained
Copyright Frequency Therapeutics, Inc. 40Appendix Copyright Frequency Therapeutics, Inc. 41
Uniqueness of Our PCA Approach
Previous approaches Frequency’s PCA approach
Stem cell
Pluripotent
Multipotent
Yamanaka 4 factors
Partial reprogramming
Bipotent
Transdifferentiation
Fully
differentiated
Hair Progenitor Hair Progenitor
cell cell cell cell
Copyright Frequency Therapeutics, Inc. Based on Conrad Waddington’s Epigenetic Landscape 42Progenitors in Place to Replace Hair Cell Loss
Human Cochlear Cross-section Audiogram
Hearing loss
correlates
with hair cell
loss
Normal Ion Transport
Despite Hair Cell Loss, Progenitor Cells Remain Normal Nerve Function
47 Year Old Male with Occupational Noise Deafness
Copyright Frequency Therapeutics, Inc. Analysis in Partnership with Mass Eye and Ear Institute Temporal Bone Bank 43Astellas Collaboration
• Development and commercialization collaboration for FX-322, including lifecycle improvements
• Astellas has ex-US rights; Frequency retains US rights to FX-322
• Payments of up to $625mm which included $80mm upfront
– Development milestone payments to Frequency of $65.0 million and $25.0 million upon the first
dosing of a patient in a Phase 2b clinical trial for SNHL in Europe and Asia, respectively
– $100.0 million and $40.0 million upon the first dosing of a patient in a Phase 3 clinical trial for
SNHL in Europe and Asia, respectively
• Development & commercialization:
– Astellas responsible for execution and costs of ex-US clinical development and commercialization
• Strategic commitment to invest in ENT as a
therapeutic area
• Research focus in regenerative medicine
• Global footprint in major markets and
distributorship model in Africa/ME and LATAM
Copyright Frequency Therapeutics, Inc. 44Proven Leadership Team
David Lucchino Chris Loose, Ph.D. Carl Lebel, Ph.D.
President, CEO & Co-Founder Chief Scientific Officer & Co-Founder Chief Development Officer
Former CEO of Entrega Bio (PureTech). Co- Co-founder/CTO of Semprus BioSciences through Chief Scientific Officer of Otonomy (2009 to
founder/CEO of Semprus BioSciences (acquired), FDA/CE clearance and acquisition. Princeton, MIT, 2016). Executive Director, Amgen. Scientific
Polaris Partners. MIT Sloan Fellow. Hertz Fellow and Yale Faculty. fellow of the American Academy of
Otolaryngology.
Dana Hilt, M.D. William Chin, M.D. Will McLean, Ph.D.
Chief Medical Officer EVP, Clinical & Translational Science VP, Biology & Regen. Med, Co-Founder
Neurologist and neuroscientist with two decades SVP, Discovery Research and Clinical Investigation 15 years experience in inner ear biology.
in biopharma and CNS drug development. at Eli Lilly, EVP at PhRMA, Executive Dean for Discovered specific stem cells that make hair
Amgen, Lysosomal, Forum Pharma. Research at Harvard Medical School. cells and neurons. Harvard-MIT Health
Sciences and Technology Program.
Copyright Frequency Therapeutics, Inc. 45Hearing Clinical Advisory Board
Dan Lee, M.D. Rene Gifford, Ph.D. Steve Rauch, M.D. Ruth Litovsky, Ph.D.
Director, Pediatric Otology Associate Director of Director, Vestibular Division, Professor, Communications
and Neurotology, Pediatric Audiology, Director Medical Director, Mass. Eye Sciences and Disorders and
Mass Eye and Ear of Cochlear Implant Program, and Ear Balance and Surgery Division of Otolaryngology,
Vanderbilt University Vestibular Center University of Wisconsin
Chris Runge, Ph.D. David Friedland, M.D., Ph.D. Julie Arenberg, MS, Ph.D. Joni Doherty, MD, Ph.D.
Chief of the Division of Vice-Chair of the Department of Associate Director of Clinical Assistant Professor of Clinical
Communication Sciences, Otolaryngology and Audiology for Research and Otolaryngology-Head and Neck
Medical College of Wisconsin Communications Sciences, Education, Mass Eye and Ear Surgery, Keck School of Medicine
Medical College of Wisconsin of USC.
Copyright Frequency Therapeutics, Inc. 46Regenerative Medicine Advisory Board Jeff Karp, Ph.D. Robert Langer, SC.D. Robin Franklin, Ph.D. Sheng Ding, Ph.D. Associate Professor at David H. Koch Institute Professor Professor of Stem Cell Medicine, Senior Investigator, Gladstone Brigham and Women’s Hospital, at the Massachusetts Institute Wellcome Trust-MRC Cambridge Institute of Cardiovascular Disease Harvard Medical School of Technology Stem Cell Institute Sean J. Morrison, Ph.D. Siddhartha Mukherjee, Amy Wagers, Ph.D. Director of the Children's Medical Center M.D., D.Phil. Forst Family Professor of Research Institute, Assistant Professor of Medicine, Stem Cell and Regenerative Biology, UT Southwestern Columbia University Medical Center Harvard University Copyright Frequency Therapeutics, Inc. 47
Frequency Therapeutics
Corporate Overview
September 2020
Copyright Frequency Therapeutics, Inc. 48You can also read
